Logo ofBalsm Alofoq Medical Co.
Balsm Alofoq Medical Co.’s shareholders disapproved the appointment of an auditor to review and audit the company’s preliminary financial statements for H1 2025, FY 2025, and H1 2026, in addition to setting his fees.
This came during the extraordinary general meeting (EGM) held on June 22, according to a statement to Tadawul.
Other agenda items were approved, and the board of directors was authorized to distribute interim dividends on a semi-annual or quarterly basis for 2025, the statement added.
Logo ofBalsm Alofoq Medical Co.
Balsm Alofoq Medical Co.’s shareholders disapproved the appointment of an auditor to review and audit the company’s preliminary financial statements for H1 2025, FY 2025, and H1 2026, in addition to setting his fees.
This came during the extraordinary general meeting (EGM) held on June 22, according to a statement to Tadawul.
Other agenda items were approved, and the board of directors was authorized to distribute interim dividends on a semi-annual or quarterly basis for 2025, the statement added.
